Discover
EVGN
Evogene Ltd.
0.44
2 x 0.31
2 x 0.55
bid
ask
+
0.01
1.80%
2 @ 04:00 PM
0.45 +0.01 (2.04%)
| Ytd | -59.91% | |
| 1y | -67.09% |
0.42
day range
0.44
0.37
52 week range
1.50
| Open | 0.44 | Prev Close | 0.43 | Low | 0.42 | High | 0.44 | Mkt Cap | 5.34M |
| Vol | 131.11K | Avg Vol | 1.10M | EPS | -1.70 | P/E | N/A | Forward P/E | -0.39 |
| Beta | 1.08 | Short Ratio | 0.04 | Inst. Own | 11.12% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-20 | 50-d Avg | 0.66 | 200-d Avg | 0.95 | 1yr Est | 8.13 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-21 | 2024-09 | 0 | -1.31 | N/A | N/A |
| 2024-08-22 | 2024-06 | 0 | -1.06 | N/A | N/A |
| 2024-05-23 | 2024-03 | 0 | -0.8 | N/A | N/A |
| 2024-03-07 | 2023-12 | -1.4 | -1.3 | 0.1 | 7.14% |
| 2023-11-15 | 2023-09 | -1.7 | -0.8 | 0.9 | 52.94% |
| 2023-08-17 | 2023-06 | -1.9 | -1.7 | 0.2 | 10.53% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-23 | Lake Street | Upgrade | Buy | Buy |
| 2023-10-02 | Alliance Global Partners | Upgrade | Buy | |
| 2023-08-18 | Lake Street | Upgrade | Buy | Buy |
| 2023-07-21 | Roth MKM | Upgrade | Buy | Buy |
| 2023-05-02 | Lake Street | Upgrade | Buy | |
| 2022-09-12 | Aegis Capital | Upgrade | Buy |
Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-03-30 | SilverArc Capital Management, LLC | 308.55K | 416.54K | 0.61% |
| 2024-03-30 | Morgan Stanley | 28.40K | 38.35K | 0.06% |
| 2024-03-30 | BNP Paribas Financial Markets | 9.14K | 12.34K | 0.02% |
| 2024-03-30 | LPL Financial LLC | 6.68K | 9.02K | 0.01% |
| 2024-03-30 | JP Morgan Chase & Company | 3.94K | 5.32K | 0.01% |
| 2024-03-30 | UBS Group AG | 6.25K | 8.44K | 0.01% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-05-30 | Fidelity NASDAQ Composite Index Fund | 5.90K | 7.97K | 0.01% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2024-07-25 |
| 0.5 : 1 | 2013-11-19 |